Dec 11, 2023
As the battle intensifies among AbbVie, Johnson & Johnson, AstraZeneca, and BeiGene in the BTK inhibitor market, Eli Lilly stands out by forging a new direction in the landscape of blood cancer drugs. Just at the beginning of this month, the FDA granted accelerated approval to Lilly’s Jaypirca. This approval is...
Read More...
Jun 09, 2020
Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1 Primary Hyperoxaluria Type 1 (PH1) is a rare disorder that affects kidneys due to an excess buildup of oxalate, which in normal cases is filtered through the kidneys...
Read More...
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Newsletter/Whitepaper